New preventatives in development.
4 posters
Page 1 of 1
New preventatives in development.
They are apparently making good progress on new drugs that specifically target migraines (as opposed to most preventatives which were all developed for other diseases). Maybe 5 years out to hit the market. I guess it's something...
http://www.medscape.com/viewarticle/827838
http://www.medscape.com/viewarticle/827838
Last edited by Migrainegirl on Sat 05 Jul 2014, 4:24 pm; edited 1 time in total (Reason for editing : Corrected link)
Migrainegirl- Four Star
- Posts : 331
Points : 377
Join date : 2011-02-13
Location : Arizona
Re: New preventatives in development.
Do you have a link that doesn't require a login? I'm guessing this is CGRP.
Platypus- Three Star
- Posts : 138
Points : 168
Join date : 2012-11-07
Re: New preventatives in development.
It doesn't ask me for a login, but here is an excerpt.
" There is growing anticipation in the headache community about the arrival of a variety of monoclonal antibodies that target the calcitonin gene-related peptide (CGRP) pathway to prevent migraine headaches.
CGRP is involved in the pathophysiology of migraine. Levels of CGRP are elevated during migraine attacks and decrease with resolution of the attacks.
Several pharmaceutical companies are developing agents that block CGRP activity, with relevant research being showcased here at the American Headache Society (AHS) 56th Annual Scientific Meeting.
Revolutionary
Although approval is likely 5 or more years away, when these drugs do become available, it will be "revolutionary," commented Peter Goadsby, MD, PhD, Director, Headache Center, University of California, San Francisco. "This is the first mechanism-based, migraine-specific therapy for prevention that we have ever had."
Although triptans represent acute treatments for migraine, "these new agents are preventive, which we have not had before," he added.
One of the agents, ALD403 (Alder BioPharmaceuticals Inc), is a genetically engineered humanized CGRP antibody delivered intravenously. A double-blind trial that randomly assigned patients to receive either the drug (n = 81) or placebo (n = 82) found that more participants receiving the drug had reduced migraine days compared with those receiving placebo.
At week 9 to 12, for example, 75.3% of the ALD 403 and 66.7% of the placebo groups had a 50% reduction in migraine days (P = .1603). The respective percentages for a 75% and 100% reduction in migraine days were 53.4% vs 30.8% (P = .0039) and 41.1% vs 16.7% (P = .0008), respectively.
"We regard a 50% reduction in headaches as a success, but in this study, there were a significant proportion of people who had a 75%, and even a 100% reduction in headaches, so it's very exciting," said Dr. Goadsby."
" There is growing anticipation in the headache community about the arrival of a variety of monoclonal antibodies that target the calcitonin gene-related peptide (CGRP) pathway to prevent migraine headaches.
CGRP is involved in the pathophysiology of migraine. Levels of CGRP are elevated during migraine attacks and decrease with resolution of the attacks.
Several pharmaceutical companies are developing agents that block CGRP activity, with relevant research being showcased here at the American Headache Society (AHS) 56th Annual Scientific Meeting.
Revolutionary
Although approval is likely 5 or more years away, when these drugs do become available, it will be "revolutionary," commented Peter Goadsby, MD, PhD, Director, Headache Center, University of California, San Francisco. "This is the first mechanism-based, migraine-specific therapy for prevention that we have ever had."
Although triptans represent acute treatments for migraine, "these new agents are preventive, which we have not had before," he added.
One of the agents, ALD403 (Alder BioPharmaceuticals Inc), is a genetically engineered humanized CGRP antibody delivered intravenously. A double-blind trial that randomly assigned patients to receive either the drug (n = 81) or placebo (n = 82) found that more participants receiving the drug had reduced migraine days compared with those receiving placebo.
At week 9 to 12, for example, 75.3% of the ALD 403 and 66.7% of the placebo groups had a 50% reduction in migraine days (P = .1603). The respective percentages for a 75% and 100% reduction in migraine days were 53.4% vs 30.8% (P = .0039) and 41.1% vs 16.7% (P = .0008), respectively.
"We regard a 50% reduction in headaches as a success, but in this study, there were a significant proportion of people who had a 75%, and even a 100% reduction in headaches, so it's very exciting," said Dr. Goadsby."
Migrainegirl- Four Star
- Posts : 331
Points : 377
Join date : 2011-02-13
Location : Arizona
Re: New preventatives in development.
It doesn't ask me for a login, but here is an excerpt.
" There is growing anticipation in the headache community about the arrival of a variety of monoclonal antibodies that target the calcitonin gene-related peptide (CGRP) pathway to prevent migraine headaches.
CGRP is involved in the pathophysiology of migraine. Levels of CGRP are elevated during migraine attacks and decrease with resolution of the attacks.
Several pharmaceutical companies are developing agents that block CGRP activity, with relevant research being showcased here at the American Headache Society (AHS) 56th Annual Scientific Meeting.
Revolutionary
Although approval is likely 5 or more years away, when these drugs do become available, it will be "revolutionary," commented Peter Goadsby, MD, PhD, Director, Headache Center, University of California, San Francisco. "This is the first mechanism-based, migraine-specific therapy for prevention that we have ever had."
Although triptans represent acute treatments for migraine, "these new agents are preventive, which we have not had before," he added.
One of the agents, ALD403 (Alder BioPharmaceuticals Inc), is a genetically engineered humanized CGRP antibody delivered intravenously. A double-blind trial that randomly assigned patients to receive either the drug (n = 81) or placebo (n = 82) found that more participants receiving the drug had reduced migraine days compared with those receiving placebo.
At week 9 to 12, for example, 75.3% of the ALD 403 and 66.7% of the placebo groups had a 50% reduction in migraine days (P = .1603). The respective percentages for a 75% and 100% reduction in migraine days were 53.4% vs 30.8% (P = .0039) and 41.1% vs 16.7% (P = .0008), respectively.
"We regard a 50% reduction in headaches as a success, but in this study, there were a significant proportion of people who had a 75%, and even a 100% reduction in headaches, so it's very exciting," said Dr. Goadsby."
" There is growing anticipation in the headache community about the arrival of a variety of monoclonal antibodies that target the calcitonin gene-related peptide (CGRP) pathway to prevent migraine headaches.
CGRP is involved in the pathophysiology of migraine. Levels of CGRP are elevated during migraine attacks and decrease with resolution of the attacks.
Several pharmaceutical companies are developing agents that block CGRP activity, with relevant research being showcased here at the American Headache Society (AHS) 56th Annual Scientific Meeting.
Revolutionary
Although approval is likely 5 or more years away, when these drugs do become available, it will be "revolutionary," commented Peter Goadsby, MD, PhD, Director, Headache Center, University of California, San Francisco. "This is the first mechanism-based, migraine-specific therapy for prevention that we have ever had."
Although triptans represent acute treatments for migraine, "these new agents are preventive, which we have not had before," he added.
One of the agents, ALD403 (Alder BioPharmaceuticals Inc), is a genetically engineered humanized CGRP antibody delivered intravenously. A double-blind trial that randomly assigned patients to receive either the drug (n = 81) or placebo (n = 82) found that more participants receiving the drug had reduced migraine days compared with those receiving placebo.
At week 9 to 12, for example, 75.3% of the ALD 403 and 66.7% of the placebo groups had a 50% reduction in migraine days (P = .1603). The respective percentages for a 75% and 100% reduction in migraine days were 53.4% vs 30.8% (P = .0039) and 41.1% vs 16.7% (P = .0008), respectively.
"We regard a 50% reduction in headaches as a success, but in this study, there were a significant proportion of people who had a 75%, and even a 100% reduction in headaches, so it's very exciting," said Dr. Goadsby."
Migrainegirl- Four Star
- Posts : 331
Points : 377
Join date : 2011-02-13
Location : Arizona
Re: New preventatives in development.
This sounds very promising. It is actually targeting the gene. I am hopeful for this CGRP. I am 60 years old and still battling headaches everyday with an occasional migraine. Thank you for the information.
kimsmom
kimsmom
kimsmom- Three Star
- Posts : 116
Points : 146
Join date : 2010-11-08
Location : Southeastern United States
Re: New preventatives in development.
It asks me for log in, too, so thanks for the excerpt. I am very hopeful, too, and can't wait!
Kinda tired of triptans being out there only -not to knock them down, though, as they do work. thanks God for them!
Risa
Kinda tired of triptans being out there only -not to knock them down, though, as they do work. thanks God for them!
Risa
Cluelesskitty- Admin
- Posts : 1534
Points : 1963
Join date : 2011-03-18
Location : BC Canada
Re: New preventatives in development.
Yeah CGRP is the great hope in HA treatment. I hope it's less than 5 years away. The other one everybody is waiting for is BOL-148 aka non-hallucinogenic LSD, which is being clinically trialed for migraine and cluster HA.
Platypus- Three Star
- Posts : 138
Points : 168
Join date : 2012-11-07
Similar topics
» Preventative medications...
» Thinking about trying preventatives....again
» Back on the preventatives again...
» New pain killers in development
» Thinking about trying preventatives....again
» Back on the preventatives again...
» New pain killers in development
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum
|
|